A Phase 1 interventional study of [^14C]-LY2835219 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon [\^14C]. [\^14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered.
In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected.
This study will last about 3 weeks for each participant, not including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) \[\^14C\] labeled drug
Drug: [^14C]-LY2835219
Administered as oral solution
Also known as: abemaciclib
Urinary and Fecal Excretion of LY2835219-Related Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
The percentage of the total radioactive dose administered that was excreted in urine or feces = (amount of radioactive dose recovered in urine or feces / total radioactive dose administered) \* 100.
Time frame: Predose up to Day 14 postdose; Fecal samples collected at 24-hour (h) intervals; Urine collected at 0 to 6 h, 6 to 12 h, and 12 to 24 h postdose and at 24-h intervals thereafter up to Day 14 postdose
Plasma Pharmacokinetics (PK) of LY2835219 and Metabolite of LY2835219: Maximum Observed Concentration (Cmax)
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Plasma PK of Radioactivity: Cmax
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Plasma PK of LY2835219, Metabolite of LY2835219, and Radioactivity: Time of Maximum Observed Concentration (Tmax)
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Plasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration-Time Curve From Time Zero to the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Plasma PK of Radioactivity: AUC(0 to Tlast)
The PK of radioactivity was measured as nanogram equivalents times hours per gram (ng Eq\*h/g).
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Plasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)]
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Plasma PK of Radioactivity: AUC(0-∞)
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Relative Abundance of LY2835219 and Metabolites of LY2835219 Eliminated in Urine and Feces
The abundance (as percentage dose) of LY2835219 or its metabolites eliminated in feces is calculated as = (amount of LY2835219 or its metabolites recovered in feces / total amount administered) \* 100. Due to low radioactivity of dose recovered in urine, further quantitative profiling of urine was not conducted.
Time frame: Predose through 216 h postdose; Fecal samples collected at 24-h intervals
Relative Abundance of LY2835219 and Metabolites of LY2835219 in Plasma
The relative abundance of LY2835219 or its metabolites in plasma were estimated based on AUC(0-∞) and reported as a percentage of total plasma radioactivity. The relative abundance of LY2835219 or its metabolites calculated as = \[AUC (0-∞) of LY2835219 or its metabolites in plasma / AUC (0-∞) of total plasma radioactivity\] \* 100.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
| Milestone | [^14C]-LY2835219 |
|---|---|
| Started | 6 |
| Received study drug | 6 |
| Completed | 6 |
| Not completed | 0 |
The percentage of the total radioactive dose administered that was excreted in urine or feces = (amount of radioactive dose recovered in urine or feces / total radioactive dose administered) \* 100.
| percentage radioactive dose administered | [^14C]-LY2835219 |
|---|---|
| Urine | 3.43 ± 2.20 |
| Feces | 81.0 ± 6.71 |
| nanograms per milliliter (ng/mL) | [^14C]-LY2835219 |
|---|---|
| LY2835219 | 63.7 ± 49 |
| M20 | 30.9 ± 19 |
| nanogram equivalents per gram (ng Eq/g) | [^14C]-LY2835219 |
|---|---|
| Plasma PK of Radioactivity: Cmax | 123 ± 27 |
| h | [^14C]-LY2835219 |
|---|---|
| LY2835219 | 8.00 (6.00 to 8.00) |
| M20 | 8.00 (6.00 to 10.00) |
| Total Radioactivity | 8.00 (6.00 to 10.00) |
| nanograms*hour/milliliter (ng*h/mL) | [^14C]-LY2835219 |
|---|---|
| LY2835219 | 2310 ± 85 |
| M20 | 1760 ± 43 |
The PK of radioactivity was measured as nanogram equivalents times hours per gram (ng Eq\*h/g).
| ng Eq*h/g | [^14C]-LY2835219 |
|---|---|
| Plasma PK of Radioactivity: AUC(0 to Tlast) | 6580 ± 41 |
| ng*h/mL | [^14C]-LY2835219 |
|---|---|
| LY2835219 | 2370 ± 83 |
| M20 | 1830 ± 42 |
| ng Eq*h/g | [^14C]-LY2835219 |
|---|---|
| Plasma PK of Radioactivity: AUC(0-∞) | 7010 ± 42 |
The abundance (as percentage dose) of LY2835219 or its metabolites eliminated in feces is calculated as = (amount of LY2835219 or its metabolites recovered in feces / total amount administered) \* 100. Due to low radioactivity of dose recovered in urine, further quantitative profiling of urine was not conducted.
| percentage of radioactive dose excreted | [^14C]-LY2835219 |
|---|---|
| LY2835219 | 7 |
| Metabolites | 52 |
The relative abundance of LY2835219 or its metabolites in plasma were estimated based on AUC(0-∞) and reported as a percentage of total plasma radioactivity. The relative abundance of LY2835219 or its metabolites calculated as = \[AUC (0-∞) of LY2835219 or its metabolites in plasma / AUC (0-∞) of total plasma radioactivity\] \* 100.
| percentage of total plasma radioactivity | [^14C]-LY2835219 |
|---|---|
| LY2835219 | 34 |
| Metabolites | 44 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| [^14C]-LY2835219 | — | 0/6 (0%) | 4/6 (66.7%) |
| Event | [^14C]-LY2835219 |
|---|---|
| Vessel Puncture Site HaematomaGeneral disorders | 2/6 |
| Vessel Puncture Site PainGeneral disorders | 1/6 |
| Vessel Puncture Site SwellingGeneral disorders | 1/6 |
| FolliculitisInfections and infestations | 1/6 |
| ExcoriationInjury, poisoning and procedural complications | 1/6 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/6 |
| HeadacheNervous system disorders | 1/6 |
| ChokingRespiratory, thoracic and mediastinal disorders | 1/6 |
Participants who received study drug.
| Age, Categorical(Participants) | [^14C]-LY2835219 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 6 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | [^14C]-LY2835219 |
|---|---|
| Female | 3 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | [^14C]-LY2835219 |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | [^14C]-LY2835219 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | [^14C]-LY2835219 |
|---|---|
| United States | 6 |
The record gives a start of Aug 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib